An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Parainfluenza

Interventions

DRUG: DAS181-F02 Dry Powder in Bulk
DRUG: DAS181-F02 Nebulized Formulation Inhaled Dose

Sponsor

Ansun Biopharma, Inc.